A randomized clinical trial investigated selenium supplementation in patients with mild-to-moderate Graves ophthalmopathy (GO) in selenium-sufficient regions. The study found no significant benefit in improving quality of life or clinical outcomes at 6 months, but showed potential short-term improvements at 3 months. The researchers suggested selenium supplementation may have potential as an adjunct therapy for GO management, but further research is needed before establishing clinical practice guidelines, especially in selenium-deficient populations. 

Source: JAMA Ophthalmology